CEL SCI CORP — Investor Relations & Filings
CEL-SCI Corporation is a clinical-stage biotechnology company engaged in the research and development of immunotherapies for cancer, autoimmune, and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a neoadjuvant treatment designed to stimulate a patient's immune system to fight cancer before standard treatments like surgery, radiation, and chemotherapy are administered. The company has completed a global pivotal Phase III clinical trial for Multikine in patients with advanced primary, previously untreated squamous cell carcinoma of the head and neck. The study demonstrated a significant 5-year overall survival benefit in a specific patient subgroup. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) technology platform for potential treatments of autoimmune and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| FORM 8-K ITEM 8.01 FDA | 2017-06-29 | English | |
| PRIMARY DOCUMENT | 2017-06-23 | English | |
| 8-K RE SUBSCRIPTION AGREE | 2017-06-22 | English | |
| 8-K RE CLOSE INVESTIGATION | 2017-06-15 | English | |
| 8-K RE REVERSE SPLIT & VOTE MEETING | 2017-06-13 | English | |
| PROSPECTUS SUPPLEMENT | 2017-06-08 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2017
15 filings
| |||||
| 9418464 | FORM 8-K ITEM 8.01 FDA | 2017-06-29 | English | ||
| 9418465 | PRIMARY DOCUMENT | 2017-06-23 | English | ||
| 9418466 | 8-K RE SUBSCRIPTION AGREE | 2017-06-22 | English | ||
| 9418468 | 8-K RE CLOSE INVESTIGATION | 2017-06-15 | English | ||
| 9418469 | 8-K RE REVERSE SPLIT & VOTE MEETING | 2017-06-13 | English | ||
| 9418470 | PROSPECTUS SUPPLEMENT | 2017-06-08 | English | ||
| 9418471 | CURRENT REPORT | 2017-06-07 | English | ||
| 9418472 | CURRENT REPORT | 2017-06-06 | English | ||
| 9418473 | FORM 8-K ITEM 8.01 | 2017-05-12 | English | ||
| 9418474 | DEFIN PROXY ANNUAL MEETING ADD'L MATERIALS | 2017-05-11 | English | ||
| 9418477 | QUARTERLY REPORT | 2017-05-10 | English | ||
| 9418479 | PROSPECTUS SUPPLEMENT | 2017-05-02 | English | ||
| 9418478 | FORM 8-K ITEM 1.01 RE SERIES KK WARRANTS | 2017-05-02 | English | ||
| 9418486 | ARS | 2017-04-27 | English | ||
| 9418487 | DEFIN PROXY RE ANNUAL MEETING | 2017-04-27 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
CEL SCI CORP via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34401/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34401 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34401 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34401 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34401}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CEL SCI CORP (id: 34401)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.